Management of refractory ascites and hepatorenal syndrome

Curr Gastroenterol Rep. 2011 Feb;13(1):17-25. doi: 10.1007/s11894-010-0156-6.

Abstract

One of the most common manifestations of the development of portal hypertension in the patient with cirrhosis is the appearance of ascites. Once ascites develops, the prognosis worsens and the patient becomes susceptible to complications such as bacterial peritonitis, hepatic hydrothorax, hyponatremia, and complications of diuretic therapy. As the liver disease progresses, the ascites becomes more difficult to treat and many patients develop renal failure. Most patients can be managed by diuretics which, when used correctly, will control the ascites. Spontaneous bacterial peritonitis can be treated effectively, but portends a worse prognosis. Once the ascites becomes refractory to diuretics, liver transplantation is the best option, although use of transjugular intrahepatic portosystemic shunts will control the ascites in many patients. Lastly, the development of hepatorenal syndrome indicates the patient's liver disease is advanced, and transplantation again is the best option. However, use of vasoconstrictors may improve renal function in some patients, helping in their management while they await a liver transplant.

MeSH terms

  • Acute Kidney Injury / diagnosis
  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / therapy
  • Ascites / complications
  • Ascites / physiopathology
  • Ascites / therapy*
  • Diagnosis, Differential
  • Diuretics / therapeutic use
  • Hepatorenal Syndrome / diagnosis
  • Hepatorenal Syndrome / etiology
  • Hepatorenal Syndrome / prevention & control
  • Hepatorenal Syndrome / therapy*
  • Humans
  • Hydrothorax / etiology
  • Hydrothorax / therapy
  • Hypertension, Portal / physiopathology
  • Hyponatremia / etiology
  • Hyponatremia / therapy
  • Liver Cirrhosis / physiopathology
  • Liver Transplantation
  • Opportunistic Infections / complications
  • Peritonitis / complications
  • Peritonitis / drug therapy
  • Portasystemic Shunt, Transjugular Intrahepatic
  • Prognosis
  • Renal Replacement Therapy
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Diuretics
  • Vasoconstrictor Agents